BiotechTube

Dapagliflozin + Placebo

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Conditions

Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

Trial Timeline

Feb 8, 2017 → Jul 17, 2019

NCT ID
NCT03036124

About Dapagliflozin + Placebo

Dapagliflozin + Placebo is a phase 3 stage product being developed by AstraZeneca for Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The current trial status is completed. This product is registered under clinical trial identifier NCT03036124. Target conditions include Chronic Heart Failure With Reduced Ejection Fraction (HFrEF).

What happened to similar drugs?

20 of 20 similar drugs in Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) were approved

Approved (20) Terminated (3) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved
✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (20)

NCT IDPhaseStatus
NCT04792190ApprovedCompleted
NCT04869124ApprovedCompleted
NCT04564742Phase 3Completed
NCT04363697ApprovedCompleted
NCT04475042Phase 2UNKNOWN
NCT02981966ApprovedCompleted
NCT03619213Phase 3Completed
NCT03387683ApprovedCompleted
NCT02956811ApprovedCompleted
NCT03036124Phase 3Completed
NCT03036150Phase 3Completed
NCT02796170ApprovedCompleted
NCT02520518Phase 2Terminated
NCT02459353ApprovedCompleted
NCT02371187Phase 2Completed
NCT02426541ApprovedCompleted
NCT01392677Phase 3Completed
NCT01042977Phase 3Completed
NCT01031680Phase 3Completed
NCT00984867Phase 3Completed

Competing Products

20 competing products in Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)

See all competitors
ProductCompanyStageHype Score
Levofloxacin 500Dr. Reddy's LaboratoriesPre-clinical
23
mRNA-0184ModernaPhase 1
0
Lubiprostone + Lubiprostone + PlaceboDr. Reddy's LaboratoriesPhase 3
37
macitentan 10 mgBML, Inc.Phase 3
32
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
29
TERN-701Terns PharmaceuticalsPhase 1/2
36
Fludarabine + Cyclophosphamide + PRGN-3007PrecigenPhase 1
23
LY3556050 + PlaceboEli LillyPhase 2
35
THB001Third Harmonic BioPhase 1
11
BriquilimabJasper TherapeuticsPhase 1/2
26
BriquilimabJasper TherapeuticsPhase 1/2
14
BriquilimabJasper TherapeuticsPhase 2
29
Empagliflozin + Matching placeboEli LillyPhase 3
40
LY3461767 + PlaceboEli LillyPhase 1
29
Pirtobrutinib + Venetoclax + RituximabEli LillyPhase 3
44
LY3526318 + PlaceboEli LillyPhase 2
35
PirtobrutinibEli LillyPhase 2
42
Ibrutinib + LY3214996Eli LillyPhase 1
21
Pirtobrutinib + AcalabrutinibEli LillyPhase 2
27
LYR-210Lyra TherapeuticsPhase 2
25